Valuation: ABVC BioPharma, Inc.

Market Cap 38.66M 33.9M 31.25M 29.25M 54.86M 3.65B 56M 376M 145M 1.8B 145M 142M 6.25B P/E 2024
-1.4x
P/E 2025 -5.42x
Enterprise Value 41.39M 36.29M 33.45M 31.32M 58.73M 3.9B 59.95M 402M 156M 1.93B 155M 152M 6.69B EV / Sales 2024
19.8x
EV / Sales 2025 -
Free-Float
79.2%
Yield 2024 *
-
Yield 2025 -
1 day+5.52%
1 week+13.33%
Current month+8.51%
1 month+18.60%
3 months+44.34%
6 months-37.04%
Current year-28.17%
1 week 1.28
Extreme 1.28
1.58
1 month 1.19
Extreme 1.19
1.58
Current year 0.88
Extreme 0.8801
2.43
1 year 0.88
Extreme 0.8801
5.48
3 years 0.4
Extreme 0.4
6.87
5 years 0.4
Extreme 0.4
116.9
10 years 0.4
Extreme 0.4
378
Manager TitleAgeSince
Chief Executive Officer 40 2023-06-22
Chief Executive Officer 39 2015-06-30
Chief Tech/Sci/R&D Officer 72 2023-06-12
Director TitleAgeSince
Director/Board Member 61 2022-07-09
Director/Board Member 70 -
Chairman 39 2015-06-30
Date Insider Type Main position Quantity % Market Cap.
22-05-19Other

Chairman

7,908,805 26.0954%
21-08-01Other

Chief Executive Officer

18,404 0.0752%
21-08-01Other

Director

6,067 0.0248%
Change 5-day change 1-year change 3-year change Capi.($)
+5.52%+13.33%-30.14%-73.11% 38.66M
+0.33%+1.37%+64.03%+119.11% 55.63B
+0.82%+15.05%+79.93%+84.34% 52.25B
+1.36%+0.36%-14.06%-14.69% 23.07B
-1.04%+7.91%+1.61%+419.24% 22.41B
-0.18%+7.20%+32.16%-14.07% 17.32B
-1.10%+4.00%+28.70%-34.51% 15.94B
-3.35%+8.96%+132.20%+290.18% 13.47B
+2.89%+5.51%+27.11%+181.45% 13.77B
+1.31%+0.53%+28.62% - 12.43B
Average +0.66%+5.04%+35.02%+106.44% 22.63B
Weighted average by Cap. +0.26%+5.13%+48.48%+120.14%

Financials

2024 2025
Net sales 510K 447K 412K 386K 723K 48.07M 738K 4.95M 1.92M 23.76M 1.91M 1.87M 82.38M -
Net income -4.9M -4.3M -3.96M -3.71M -6.96M -463M -7.1M -47.63M -18.43M -229M -18.41M -18.01M -793M -7.91M -6.93M -6.39M -5.98M -11.22M -746M -11.45M -76.82M -29.73M -369M -29.7M -29.05M -1.28B
Net Debt 2.88M 2.53M 2.33M 2.18M 4.09M 272M 4.17M 28M 10.83M 134M 10.82M 10.59M 466M 2.73M 2.39M 2.2M 2.06M 3.87M 257M 3.95M 26.49M 10.25M 127M 10.24M 10.02M 441M
Logo ABVC BioPharma, Inc.
ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.
Employees
18
Date Price Change Volume
26-06-26 US$1.530 +5.52% 216,682
26-06-25 US$1.450 +9.02% 354,399
26-06-24 US$1.330 +1.53% 73,338
26-06-23 US$1.310 -0.76% 94,576
26-06-22 US$1.320 -2.22% 90,701
  1. Stock Market
  2. Stocks
  3. ABVC Stock